Amiodarone is an effective antiarrhythmic agent, but it carries significant risks that demand careful patient supervision and regular monitoring. Healthcare professionals should ensure they are familiar with these risks and implement robust review protocols. Amiodarone has been associated with…
Finasteride and Dutasteride: Updated Psychiatric and Sexual Dysfunction Warnings
The MHRA has completed a review of finasteride and dutasteride, two commonly prescribed medications for benign prostatic hyperplasia and male-pattern hair loss, and has identified important new safety information regarding psychiatric side effects and sexual dysfunction. The MHRA has reviewed…
Nasal Decongestant Sprays: Rebound Congestion and Overuse Risk
The MHRA has issued a safety alert regarding nasal decongestant sprays and drops containing xylometazoline hydrochloride and oxymetazoline hydrochloride. Reports indicate an increased risk of rebound congestion, rhinitis medicamentosa, and tachyphylaxis when these products are overused. Rebound…
Falsified Mounjaro KwikPen 15mg Detected in UK
The MHRA has identified a falsified version of Mounjaro (tirzepatide) KwikPen 15mg solution for injection supplied through an online pharmacy in the UK. This alert applies to a specific batch and requires immediate awareness among clinical teams and patients. Falsified product identified with…
IXCHIQ Chikungunya Vaccine Temporarily Restricted in Adults Aged 65+
The Commission on Human Medicines (CHM) has temporarily restricted the use of IXCHIQ Chikungunya vaccine in people aged 65 years and over following very rare but serious adverse events reported globally. This is a precautionary measure to allow further investigation. IXCHIQ should not be…
IXCHIQ Chikungunya vaccine: age restrictions updated following safety review
The MHRA has completed a safety review of IXCHIQ (chikungunya vaccine) and, following recommendations from the Commission on Human Medicines (CHM), important changes to its licensed indications have been made. IXCHIQ is no longer indicated for adults over 60 years of age The vaccine is…
Semaglutide and Risk of Vision Loss (NAION)
The MHRA has issued a safety update regarding a very rare but serious risk associated with semaglutide-containing medicines. Clinicians and responders should be aware of this potential adverse effect, particularly when counselling patients or assessing vision-related complaints. Non-arteritic…
GLP-1 Agonists: Strengthened Warnings on Acute Pancreatitis Risk
The MHRA has issued updated safety guidance on GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists, with strengthened warnings regarding the risk of acute pancreatitis, including necrotising and fatal cases. Product information for all GLP-1 and GLP-1/GIP agonists has been updated to…
Isotretinoin prescribing guidance and risk minimisation updates
The Commission on Human Medicines (CHM) has endorsed changes to the risk minimisation measures for isotretinoin following a review of measures implemented in 2023. Healthcare professionals are asked to review the updated guidance to ensure safe prescribing and patient management. Risk minimisation…
Updated Safety Information for Gabapentinoids, Benzodiazepines and Z-Drugs
The MHRA has completed a comprehensive review of safety information supplied with gabapentinoids (pregabalin and gabapentin), benzodiazepines, and z-drugs. The review examined warnings relating to addiction, dependence, withdrawal, and tolerance to ensure prescribers and patients have clear,…
Rybelsus (semaglutide) formulation transition and medication error risk
The MHRA has issued a safety alert regarding a planned transition to a new formulation of Rybelsus® (semaglutide tablets). During this transition period, both the original and new formulations will be in circulation. Although bioequivalent, they carry different stated mg doses, creating a…
Mesalazine and Idiopathic Intracranial Hypertension Risk
The MHRA has identified a very rare but important safety signal: idiopathic intracranial hypertension (IIH) has been reported in patients treated with mesalazine. Following review, warnings for IIH are now being added to the product information for all mesalazine products. IIH is a rare neurological…
Isotretinoin Prescribing Guidance Updates
The Commission on Human Medicines (CHM) has endorsed changes to prescribing guidance for isotretinoin. This update reflects ongoing safety monitoring and aims to optimise clinical practice across dermatology services in the UK. CHM has reviewed and endorsed updated prescribing guidance for…
#MedSafetyWeek 2025: Collective Action to Improve Medicines Safety
The MHRA is launching its annual #MedSafetyWeek campaign from 3 to 9 November 2025, with a clear message: we can all help make medicines safer. This year's campaign emphasises that medicines safety is not the responsibility of regulators and healthcare professionals alone. Patients, carers,…
Paracetamol in pregnancy remains safe; no autism link
The MHRA has issued a reminder that paracetamol remains safe to use during pregnancy and there is no evidence that it causes autism in children. This update addresses recent concerns and reinforces current clinical guidance. Paracetamol is the first-choice pain reliever for pregnant women No…
RSV Vaccines and Guillain-Barré Syndrome Risk in Older Adults
The MHRA has identified a small but increased risk of Guillain-Barré syndrome (GBS) following vaccination with two RSV vaccines in adults aged 60 years and older. Healthcare professionals should be alert to this potential adverse effect and ensure appropriate patient counselling and monitoring. A…
Valproate Reproductive Risk: Updated Safety Materials Now Available
The MHRA has published updated safety and educational materials to support healthcare professionals and patients in discussing the reproductive risks associated with valproate medicines. These resources implement regulatory measures announced in the November 2023 National Patient Safety Alert and…
Thiopurines and Intrahepatic Cholestasis of Pregnancy
The MHRA has issued a safety update regarding a rare but serious risk associated with thiopurine medications in pregnant patients. Intrahepatic cholestasis of pregnancy (ICP) has been rarely reported in patients treated with azathioprine and is believed to be a risk applicable to all drugs…
Kaftrio: Psychological Side Effects in Cystic Fibrosis Treatment
The MHRA has issued a safety update regarding psychological side effects reported in patients with cystic fibrosis treated with Kaftrio. While these effects are infrequent, healthcare professionals should be aware of the risk profile and monitor patients accordingly. Psychological side effects…
SABA Overuse in Asthma: Safety Reminder and Prescribing Guideline Changes
Healthcare professionals and patients are reminded of the significant risks associated with overuse of short-acting beta 2 agonists (SABA) in asthma management. The MHRA has issued this alert to reinforce existing safety guidance and highlight recent changes to SABA prescribing recommendations.…
About these alerts
General information for event medical professionals. Not a substitute for the MHRA alert itself, the SPC, BNF or local clinical guidelines. Each full alert on eventris.app links to its MHRA source.